← Back to Search

Axillary Block with 0.5% Ropivicaine for Arteriovenous Fistula

N/A
Waitlist Available
Led By Turlough O'Hare, MD
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Patients with ESRD undergoing radio-cephalic AVF
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour post-operatively
Awards & highlights

Summary

Once kidney function goes below 10 to 15 percent of normal, dialysis treatments or a kidney transplant are necessary to sustain life. One type of dialysis is hemodialysis which cleans blood by removing it from the body and passing it through a dialyzer, or artificial kidney. To maximize the amount of blood cleansed during hemodialysis treatments, there should be continuous high volumes of blood flow. A fistula used for hemodialysis is a direct connection of an artery to a vein. Once an arteriovenous fistula (AVF) is created it is a natural part of the body. This is the preferred type of access because once the fistula properly matures and gets bigger and stronger; it provides an access with good blood flow that can last for decades. After the fistula is surgically created, it can take weeks to months before the fistula matures and is ready to be used for hemodialysis. There have been surgical factors identified; one of them being the anesthetic used which may cause a fistula not to survive. This study will look at comparing 3 anesthetic techniques: axillary block (AB) versus stellate ganglion (SGB) block+local anesthetic versus local anesthetic (LA).

Eligible Conditions
  • Arteriovenous Fistula

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour post-operatively
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour post-operatively for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Arteriovenous fistula flow

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Stellate Ganglion Block with 0.2% RopivicaineExperimental Treatment1 Intervention
Patients will receive stellate ganglion block and local anesthetic using an ultrasound-guided technique.After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the lateral position toward the anterior aspect of longus colli muscle just posterior to the internal jugular vein. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 10 mL of 0.2% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
Group II: Axillary Block with 0.5% RopivicaineExperimental Treatment1 Intervention
Patients will receive an axillary block using an ultrasound-guided technique. After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the cephalic aspect of the transducer toward the posterior aspect of the axillary artery. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 20 mL solution of 0.5% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
Group III: Local anesthetic infiltration with 0.25% BupivicaineActive Control1 Intervention
Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.

Find a Location

Who is running the clinical trial?

McMaster UniversityLead Sponsor
906 Previous Clinical Trials
2,613,241 Total Patients Enrolled
St. Joseph's Healthcare HamiltonOTHER
199 Previous Clinical Trials
26,681 Total Patients Enrolled
Turlough O'Hare, MDPrincipal InvestigatorSt. Joseph's Healthcare Hamilton/McMaster Univeristy
~0 spots leftby Sep 2025